Read by QxMD icon Read

Inhaled nitric oxide

Chong Lei, Lorenzo Berra, Emanuele Rezoagli, Binglan Yu, Hailong Dong, Shiqiang Yu, Lihong Hou, Min Chen, Wensheng Chen, Hongbing Wang, Qijun Zheng, Jie Shen, Zhenxiao Jin, Tao Chen, Rong Zhao, Emily Christie, Venkata S Sabbisetti, Francesco Nordio, Joseph V Bonventre, Lize Xiong, Warren M Zapol
RATIONALE: No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1-year after cardiac surgery. OBJECTIVE: To determine whether administration of nitric oxide reduces the incidence of post-operative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass. METHODS: 244 Patients undergoing elective, multiple valve replacement surgery mostly due to rheumatic fever were randomized to receive either nitric oxide (treatment) or nitrogen (control)...
June 22, 2018: American Journal of Respiratory and Critical Care Medicine
Narongsak Nakwan
Persistent pulmonary hypertension of the newborn (PPHN) is a complication of several respiratory diseases characterized by an elevation in pulmonary vascular resistance with resultant right-to-left shunting of blood and severe hypoxemia in the neonatal period. PPHN carries a high rate of morbidity and mortality, particularly in limited-resource settings (low-income and/or developing country). Echocardiography remains the gold standard for diagnosis of PPHN. Modern therapies such as inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators agents can reduce the mortality rate of PPHN...
June 19, 2018: American Journal of Perinatology
Zeming Zhang, Kun Pan, Lu Chen, Yancun Wang
The aim of the present study was to investigate the effect of nitric oxide inhalation (NOI) on cardiac troponin I (CTnI) levels and mean pulmonary arterial pressure (mPAP) in rabbits with acute massive pulmonary embolism (AMPE). Thirty rabbits were used as animal models for AMPE and received different treatments. A total of 4 h after successful modeling, the control group (CON, n=10) received conventional thrombolysis, whereas the treatment group (TRE, n=10) received conventional thrombolysis plus NOI. The experimental group (EXP, n=10) did not receive any treatments...
July 2018: Experimental and Therapeutic Medicine
Pooja, Dishari Ghosh, Kalpana Bhargava, Niroj Kumar Sethy
The lower inhaled oxygen per volume at high altitude poses an intimidating challenge for humans to survive and reproduce. Indigenous populations of the Himalayas reportedly exhibit higher microcirculatory blood flow accompanied by higher orders of magnitude of nitric oxide (NO) products in lung, plasma and red blood cells as a vascular adaptation strategy for hypobaric hypoxia. The precise mechanism of such observed higher NO metabolites for hypoxia adaptation remains elusive. Studying high altitude native Ladakhi women, we observed significant higher eNOS mRNA and protein in blood/plasma as compared to lowland women...
June 9, 2018: Nitric Oxide: Biology and Chemistry
Caitlin C Jorgenson, Kirsten E Coffman, Bruce D Johnson
The single breath hold maneuver for measuring lung diffusing capacity for carbon monoxide (DLCO) and nitric oxide (DLNO) incorporates multiple sources of variability. This study examined how changes in intrathoracic pressure, inhalation time, and breath hold time affect DLCO, DLNO, alveolar-capillary membrane conductance (DmCO) and pulmonary capillary blood volume (Vc) at rest and during submaximal exercise. Thirteen healthy subjects (mean ± SD; age = 26 ± 3y) performed duplicate tests at rest and during submaximal exercise...
June 6, 2018: Respiratory Physiology & Neurobiology
Ruchi Amin, Marjorie J Arca
BACKGROUND: The use of neurally adjusted ventilator assist (NAVA) in congenital diaphragmatic hernia (CDH) patients has been historically deemed unwise, since the trigger for breaths is the electromyographic activity of the diaphragmatic muscle. We report on our NAVA experience in CDH patients. METHODS: We performed an IRB-approved retrospective review of newborns from 1/1/2012-1/1/2017 at a Level I Children's Surgery Center undergoing CDH repair. Data obtained included demographics, defect type and repair, respiratory support, and outcomes...
May 19, 2018: Journal of Pediatric Surgery
Miriam C N Eller, Karina P Vergani, Beatriz M Saraiva-Romanholo, Leila Antonangelo, Claudio Leone, Joaquim C Rodrigues
BACKGROUND: The phenotypes and endotypes of severe therapy-resistant asthma (STRA) have not been fully elucidated in children. The aim of the present study was to investigate inflammatory markers in the induced sputum of children with STRA and to compare them with those present in a group of children who achieved control. METHODS: A prospective cohort of children (6-18 years of age) diagnosed with severe asthma (GINA criteria) who had undergone treatment for at least 6 months was comprehensively followed for 3 months...
June 5, 2018: Pediatric Pulmonology
Helen L Petsky, Chris J Cates, Kayleigh M Kew, Anne B Chang
BACKGROUND: Asthma guidelines guide health practitioners to adjust treatments to the minimum level required for asthma control. As many people with asthma have an eosinophilic endotype, tailoring asthma medications based on airway eosinophilic levels (sputum eosinophils or exhaled nitric oxide, FeNO) may improve asthma outcomes. OBJECTIVE: To synthesise the evidence from our updated Cochrane systematic reviews, for tailoring asthma medication based on eosinophilic inflammatory markers (sputum analysis and FeNO) for improving asthma-related outcomes in children and adults...
June 1, 2018: Thorax
Hyun-Su Ri, Hyo Jung Son, Han Byeol Oh, Su-Young Kim, Ju Yeon Park, Ju Yeon Kim, Yoon Ji Choi
Inhaled nitric oxide (iNO) therapy is commonly used in lung transplantation (LT) recipients during the perioperative periods. However, previous studies report that the use of iNO may increase the risk of renal dysfunction. Post-LT acute kidney injury (AKI) can lead to critical situations, including prolonged intensive care unit or hospital stays and increased morbidity and mortality. Accordingly, the aim of this study was to investigate the relationship between iNO therapy and incidence of post-LT AKI in LT recipients...
June 2018: Medicine (Baltimore)
Julia Engel, Vera van Kampen, Anne Lotz, Jessica Abramowski, Vitali Gering, Olaf Hagemeyer, Thomas Brüning, Monika Raulf, Rolf Merget
PURPOSE: An increase of fractional exhaled nitric oxide (FeNO) has been described after specific inhalation challenges (SICs) with occupational allergens, but the clinical role of FeNO measurements before and after SIC is unknown. It was the aim of this study to assess the diagnostic accuracy of FeNO measurements before and after SIC in subjects with suspected occupational asthma (OA). METHODS: One hundred forty-eight patients with suspected OA were examined by SIC with various occupational allergens...
May 30, 2018: International Archives of Occupational and Environmental Health
T Arun Babu, Y Soliman, K Mohammad
Persistent pulmonary hypertension of newborn (PPHN) is a very rare manifestation of congenital cytomegalovirus (CMV) infection. PPHN associated with CMV can be severe but is usually transient and responds well to antiviral therapy. We report a rare case of PPHN that occurred in the setting of fulminant congenital CMV infection and successful treatment with antiviral therapy along with review of the very few cases reported in literature. A male appropriate for gestational Age (AGA) newborn developed rapidly progressive respiratory distress starting at 11 hours of life requiring ventilatory support and 100% oxygen...
May 23, 2018: Journal of Neonatal-perinatal Medicine
Vasantha H S Kumar, Rita Dadiz, Jamie Koumoundouros, Stephanie Guilford, Satyan Lakshminrusimha
BACKGROUND: Congenital diaphragmatic hernia (CDH) is associated with lung hypoplasia, cardiac dysfunction and pulmonary hypertension. Inhaled nitric oxide (iNO) and milrinone are commonly used pulmonary vasodilators in CDH. We studied the hemodynamic effects of iNO and milrinone in infants with CDH. METHODS: A retrospective chart review was performed of all CDH infants admitted to two regional perinatal centers and infants classified into three groups: No-iNO group; iNO-responders and iNO-nonresponders...
May 28, 2018: Pediatric Surgery International
Xiao-Ming Zhu, Qin Wang, Wei-Wei Xing, Min-Hui Long, Wen-Liang Fu, Wen-Rong Xia, Chen Jin, Ning Guo, Dong-Qun Xu, Dong-Gang Xu
The biggest victim of ambient air pollution is the respiratory system. Mainly because of the harmful components, especially the particulate matters with an aerodynamic diameter of ≤ 2.5µm (PM2.5), can be directly inhaled and deeply penetrate into the lung alveoli, thus causing severe lung dysfunction, including chronic cough, bronchitis and asthma, even lung cancer. Unfortunately, the toxicological mechanisms of PM2.5 associations with these adverse respiratory outcomes have still not been clearly unveiled...
2018: International Journal of Biological Sciences
Kevin R Ellsworth, Marc A Ellsworth, Amy L Weaver, Kristin C Mara, Reese H Clark, William A Carey
Importance: Pulmonary hypoplasia affects a very small percentage of preterm neonates, but its presence is associated with high rates of mortality. Objective: To determine whether treatment with inhaled nitric oxide during the first week of life was associated with improved in-hospital survival in a cohort of extremely preterm neonates with pulmonary hypoplasia. Design, Setting, and Participants: This cohort study used data from the Pediatrix Medical Group's Clinical Data Warehouse, a data set containing information from more than 350 neonatal intensive care units in 35 US states and Puerto Rico...
May 7, 2018: JAMA Pediatrics
Stefan P Janssens, Jan Bogaert, Jaroslaw Zalewski, Attila Toth, Tom Adriaenssens, Ann Belmans, Johan Bennett, Piet Claus, Walter Desmet, Christophe Dubois, Kaatje Goetschalckx, Peter Sinnaeve, Katleen Vandenberghe, Pieter Vermeersch, Arpad Lux, Zsolt Szelid, Monika Durak, Piotr Lech, Krzysztof Zmudka, Peter Pokreisz, Pascal Vranckx, Bela Merkely, Kenneth D Bloch, Frans Van de Werf
Aims: Inhalation of nitric oxide (iNO) during myocardial ischaemia and after reperfusion confers cardioprotection in preclinical studies via enhanced cyclic guanosine monophosphate (cGMP) signalling. We tested whether iNO reduces reperfusion injury in patients with ST-elevation myocardial infarction (STEMI; NCT01398384). Methods and results: We randomized in a double-blind, placebo-controlled study 250 STEMI patients to inhale oxygen with (iNO) or without (CON) 80 parts-per-million NO for 4 h following percutaneous revascularization...
May 24, 2018: European Heart Journal
L R Li, Z Y Cui, H C Wang, L X Song, J H Qi, P P Zhang, X Q Han, H Y Wang
Objective: To study effects of ketotifen on fractional exhaled nitric oxide in patients with combined allergic rhinitis and asthma syndrome. Method: One hundred and twelve patients with asthma were selected from department of respiration, Affiliated Hospital of North China University of science and technology from January 2016 to 2017 in March. Eighty-four patients with allergic rhinitis were selected as the subjects, Randomly divided into two groups,including observed group(n=42) and control group(n=42).The control group was treated with antitussive,expectorant and inhaled corticosteroids, while the observed group in the control group combined with ketotifen 1 mg 2/ day oral treatment,the changes of FeNO and IL-17 in the two groups were compared after one month treament...
November 5, 2017: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
L R Li, J H Qi, Z Y Cui, H C Wang, P P Zhang, X Q Han, H Y Wang
Objective: To study the effect of monrustet on fractional exhaled nitric oxide and inflammatory cytokines in the elderly with bronchial asthma combined obstructive sleep apnea hypopnea syndrome. Method: 150 cases diagnosed as asthma were enrolled in this study. The patients were divided into bronchial asthma combined with OSAHS (n=72)and bronchial asthma (n=78). According to the different treatment methods , patients were divided into observation group and control group. Two groups were given common treatment with inhaled corticosteroids, and the observation group was taken orally montrast 10mg/night additionally...
October 20, 2017: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
Shelly Domadia, S Ram Kumar, Jodie K Votava-Smith, Jay D Pruetz
The objective of this study is to evaluate neonatal outcomes of total anomalous pulmonary venous return (TAPVR) and identify fetal echocardiography findings associated with preoperative pulmonary venous obstruction (PPVO). This retrospective study evaluated TAPVR cases from 2005 to 2014 for preoperative and postoperative outcomes based on prenatal diagnosis, PPVO, and heterotaxy syndrome. Fetal pulmonary and vertical vein Dopplers were analyzed as predictors of PPVO. Of 137 TAPVR cases, 12% were prenatally diagnosed; 60% had PPVO, and 21% had heterotaxy...
May 23, 2018: Pediatric Cardiology
Richard J Russell, Latifa Chachi, J Mark FitzGerald, Vibeke Backer, Ronald Olivenstein, Ingrid L Titlestad, Charlotte Suppli Ulrik, Timothy Harrison, Dave Singh, Rekha Chaudhuri, Brian Leaker, Lorcan McGarvey, Salman Siddiqui, Millie Wang, Martin Braddock, Lars H Nordenmark, David Cohen, Himanshu Parikh, Gene Colice, Christopher E Brightling
BACKGROUND: The role of interleukin 13 in airway inflammation and remodelling in asthma is unclear. Tralokinumab is a human monoclonal antibody that neutralises interleukin 13. We aimed to evaluate whether tralokinumab would have an effect on airway eosinophilic infiltration, blood and sputum eosinophil concentrations, eosinophil activation, and airway remodelling. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled phase 2 trial at 15 centres across the UK, Denmark, and Canada...
May 18, 2018: Lancet Respiratory Medicine
Reynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, Peter Wessman, Karin Bowen, Edward Piper, Gene Colice, Christopher E Brightling
BACKGROUND: Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population. METHODS: STRATOS 1 and STRATOS 2 were randomised, double-blind, parallel-group, placebo-controlled, phase 3 clinical trials that enrolled participants aged 12-75 years with severe asthma that was inadequately controlled despite use of inhaled corticosteroids (≥500 μg per day fluticasone or equivalent) and a long-acting β2 agonist (but not oral corticosteroids)...
May 18, 2018: Lancet Respiratory Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"